Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Abstract
Context: The impact of serum androgen manipulation on prostate tissue hormone levels in normal men is unknown. Studies of men with prostate cancer have suggested that prostatic androgens are preserved in the setting of castration. Tissue androgens might stimulate prostate growth, producing adverse clinical consequences. Objective: The objective of the study was to determine the effect of serum androgen manipulation on intraprostatic androgens in normal men. Design: Thirteen male volunteers ages 35–55 yr (prostate-specific antigen < 2.0 ng/ml; normal transrectal ultrasound) were randomly assigned to: 1) a long-acting GnRH-antagonist, acyline, every 2 wk; 2) acyline plus testosterone (T) gel (10 mg/d); or 3) placebo for 28 d. Serum hormones were assessed weekly. Prostate biopsies were obtained on d 28. Extracted androgens were measured by RIA, and immunohistochemistry for androgen-regulated proteins was performed. Results: The mean decrease in serum T was 94%, whereas prostatic T and dihydrotestosterone levels were 70 and 80% lower, respectively, in subjects receiving acyline alone compared with controls (P < 0.05). Despite this decrease in prostate androgens, there were no detectable differences in prostate epithelial proliferation, apoptosis, prostate-specific antigen, and androgen receptor expression. Conclusion: In this small study of healthy subjects, despite a 94% decrease in serum T with medical castration, intraprostatic T and dihydrotestosterone levels remained 20–30% of control values, and prostate cell proliferation, apoptosis, and androgen-regulated protein expression were unaffected. Our data highlight the importance of assessing tissue hormone levels. The source of persistent prostate androgens associated with medical castration and their potential role in supporting prostate metabolism deserves further study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [38]
Citations
Cites
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082 · cited 2×
“known to be androgen-regulated (28, 29)] between the medically castrate group and the control subjects (Table 3).”
BackgroundSuicidal Tendencies: Apoptotic Cell Death by Caspase Family Proteinases
Wolf, B. B., & Green, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20049 · Cited by 942
Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002) · Urology · doi:10.1016/s0090-4295(02)01905-2 · Cited by 729
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., & Russell, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116665 · Cited by 727 · cited 1×
“The prostate expresses high levels of type II 5 -reductase (1, 2) and enzymes involved in steroid metabolism (3, 4); therefore the endocrine milieu within the prostate may substantially differ from that of serum.”
BackgroundThe Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675 · cited 3×
“(15) who found a preservation of prostate T concentrations in hormone-refractory prostate cancer despite a minimum of 6 months of medical or surgical castration.”
BackgroundResultWolf, B. B., Schuler, M., Echeverri, F., & Green, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30651 · Cited by 487
Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030330 · Cited by 467
Metabolism of anabolic androgenic steroids
Schänzer, W. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.7.1001 · Cited by 372 · cited 1×
“Although the half-life of serum T is in the order of hours (35), the half-life of tissue androgens is not known, and it is possible that longer periods of androgen ablation are required to see changes in prostate epithelial cell proliferation or apoptosis.”
BackgroundLabrie, F., Luu-The, V., Labrie, C., & Simard, J. (2001) · Frontiers in Neuroendocrinology · doi:10.1006/frne.2001.0216 · Cited by 366 · cited 2×
“Although it is possible that intraprostatic androgens arise from residual testicularderived serum androgens, the prostate has been shown to express, at least at the transcript level, all the enzymatic machinery required to convert adrenal precursors such as androstenedione, DHEA, and DHEA-S to DHT (3, 4), and increase…”
BackgroundPeters, C. A., & Walsh, P. C. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709033171004 · Cited by 337 · cited 1×
“Very small but detectable changes in total and transitional zone volume have been observed with treatment using a potent 5 -reductase inhibitor as soon as 1 month in a very large cohort (36), although a previous small study of a GnRH agonist failed to detect changes in prostate size at 1 month (37).”
Background
Cited by
Items 101–200 of 232
Saad, F., Yassin, A. A., Haider, A., & Gooren, L. J. (2011) · Arab Journal of Urology · doi:10.1016/j.aju.2011.06.003 · Cited by 23
“Rather than circulating levels of androgens, tissue androgens might stimulate prostate growth, producing adverse clinical consequences [3].”
BackgroundRaittinen, P. V. H., Syvälä, H., Tammela, T. L. J., Häkkinen, M. R., Ilmonen, P., Auriola, S. O. K., & Murtola, T. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103432 · Cited by 22
“This suggests that intraprostatic and serum steroidomic profile milieus are dissimilar and possibly under differing regulation in men with PCa [21].”
BackgroundGuidelines for Testosterone Therapy for Men: How to Avoid a Mad (T)ea Party by Getting Personal
Anawalt, B. D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0858 · Cited by 20
Prostate cancer: a newly discovered route for testosterone to reach the prostate
Gat, Y., Joshua, S., & Gornish, M. (2009) · Andrologia · doi:10.1111/j.1439-0272.2009.00972.x · Cited by 22
“The present study also provides an explanation why FT levels in prostate tissue during ADT are sufficient to activate ARs despite medical castration (Page et al., 2006; Mostaghel et al., 2007).”
BackgroundIntratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer
Knuuttila, M., Mehmood, A., Mäki-Jouppila, J. H., Ryberg, H., Taimen, P., Knaapila, J., Ettala, O. O., Boström, P. J., Ohlsson, C., Venäläinen, M. S., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0148 · Cited by 24
Quality of Life and Sexual Health in the Aging of PCa Survivors
Gacci, M., Baldi, E., Tamburrino, L., Detti, B., Livi, L., Nunzio, C. D., Tubaro, A., Gravas, S., Carini, M., & Serni, S. (2014) · International Journal of Endocrinology · doi:10.1155/2014/470592 · Cited by 19
“There is evidence that androgen levels may remain elevated in the prostate during ADT [58, 59].”
BackgroundAlsinnawi, M., Zhang, A., Bianchi-Frias, D., Burns, J., Cho, E., Zhang, X., Sowalsky, A. G., Ye, H., Slee, A. E., True, L. D., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0141-6 · Cited by 22
Self-citation5α-Reductase inhibitor treatment of prostatic diseases: background and practical implications
Dorsam, J., & Altwein, J. E. (2008) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2008.56 · Cited by 19
Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue
Zhou, Y., Otto‐Duessel, M., He, M., Markel, S., Synold, T. W., & Jones, J. O. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0060 · Cited by 21
“…hormonal contraception on intraprostatic androgen concentration and androgen action indicate that the intraprostatic level of androgen is not affected by testosterone supplementation (Marks et al. 2006, Page et al. 2006, Morgentaler & Traish 2009, Goldenberg et al. 2011, Mostaghel et al. 2012).”
InfluentialDeLay, K. J., & Köhler, T. (2016) · Urologic Clinics of North America · doi:10.1016/j.ucl.2016.04.011 · Cited by 17
Wu, Y., Tang, L., Azabdaftari, G., POP, E. A., & Smith, G. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.02.018 · Cited by 17
Tafuri, A., Porcaro, A. B., Shakir, A., Migliorini, F., Verratti, V., Brunelli, M., Cerruto, M. A., & Antonelli, A. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01625-w · Cited by 17
Adrenal Steroids and Resistance to Hormonal Blockade of Prostate and Breast Cancer
Michael, P., Roversi, G. A., Brown, K. A., & Sharifi, N. (2022) · Endocrinology · doi:10.1210/endocr/bqac218 · Cited by 17
Mostaghel, E. A., Lin, D. W., Amory, J. K., Wright, J. L., Marck, B. T., Nelson, P. S., Matsumoto, A. M., Bremner, W. J., & Page, S. T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1536 · Cited by 17
“6) Prostate volume (ml) 25 (16, 29) 22 (18, 24) 15 (14, 19) 16 (14, 17) 15 (13, 21) 15 (13, 19) 19 (14, 21) 17 (14, 19)”
BackgroundResultInfluentialSelf-citationMitsiades, N., & Bedoya (2013) · OncoTargets and Therapy · doi:10.2147/ott.s24941 · Cited by 16
“Treatment with GnRH agonists usually suppresses circulating testosterone and DHT by more than 90%, but the intraprostatic concentrations of these androgens decrease by only 60%–80%, 50,51 which highlights the importance of the extragonadal sources of androgen.”
Late‐onset hypogonadism: Prostate safety
Miranda, E., & Torres, L. O. (2020) · Andrology · doi:10.1111/andr.12772 · Cited by 18
Oxidative DNA Damage in the Prostate May Predispose Men to a Higher Risk of Prostate Cancer
Wu, J. D., Lin, D. W., Page, S. T., Lundgren, A. D., True, L. D., & Plymate, S. R. (2009) · Translational Oncology · doi:10.1593/tlo.08217 · Cited by 16
“5 ng/ml and a normal DRE result who had biopsies as part of a separate investigation [29,30].”
BackgroundSelf-citationAbiraterone acetate for castration resistant prostate cancer
Shah, S., & Ryan, C. J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003639427 · Cited by 16
“found that despite a 94% decrease in serum testosterone concentrations, intra-prostatic testosterone and DHT levels remained at 20 – 30% of control values, and furthermore, found a strong relationship between serum DHEA and prostatic tissue androgen after medical castration [18].”
BackgroundKnuuttila, M., Mehmood, A., Huhtaniemi, R., Yatkin, E., Häkkinen, M. R., Oksala, R., Laajala, T. D., Ryberg, H., Handelsman, D. J., Aittokallio, T. A., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.08.036 · Cited by 19
Biology and natural history of prostate cancer and the role of chemoprevention
Rosenberg, M. T., Froehner, M., Albala, D., & Miner, M. M. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02541.x · Cited by 18
Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer
Aragon‐Ching, J. B., & Dahut, W. L. (2010) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.02.004 · Cited by 17
“Androgen deprivation therapy (ADT) reliably decreases serum testosterone in > 90% of cases but intra-tumoral decline in androgen levels are less dramatic [9,10].”
BackgroundEmerging biological observations in prostate cancer
Shah, S., & Small, E. J. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.161 · Cited by 17
Ando, T., Nishiyama, T., Takizawa, I., Ishizaki, F., Miyashiro, Y., Takeda, K., Hara, N., & Tomita, Y. (2016) · Scientific Reports · doi:10.1038/srep32198 · Cited by 17
Wikström, P., Ohlson, N., Stattin, P. E., & Bergh, A. R. J. (2007) · The Prostate · doi:10.1002/pros.20569 · Cited by 14
“Testosterone and DHT levels in recurrent prostate cancer occur at levels sufficient to activate the AR [23,29] and, moreover, increased levels of AR coactivators such as SRC-1 and TIF2 have been suggested to enhance AR activity and tumor progression after androgen ablation [30,31].”
BackgroundSimmons, M. N., & Klein, E. A. (2009) · Urology · doi:10.1016/j.urology.2008.09.040 · Cited by 17
Bordeau, B. M., Ciulla, D. A., & Callahan, B. P. (2016) · ChemMedChem · doi:10.1002/cmdc.201600238 · Cited by 13
Miyazaki, Y., Teramoto, Y., Shibuya, S., Goto, T., Okasho, K., Mizuno, K., Uegaki, M., Yoshikawa, T., Akamatsu, S., Kobayashi, T., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050601 · Cited by 13
“ADT is required to treat advanced PCa and biochemical recurrent cases after curative radical treatment; however, despite the reduction of serum testosterone (T) to castration levels and an observed tumor response in 80%–90% of the patients, residual concentrations of intratumoral 5α-dihydrotestosterone (DHT) remain at…”
BackgroundIntratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer
Ye, J., Xie, Y., Wang, J., Wu, R., Li, D., Yoo, K. H., Wusiman, D., Cho, W. C., Lyu, Z., & Feng, D. (2026) · Research · doi:10.34133/research.1128 · Cited by 17
“…the critical roles of (a) local de novo synthesis in the prostate, (b) uptake and conversion of adrenal-derived androgen precursors, and (c) intratumoral regulation of androgen metabolism, in maintaining active androgen levels within tumors under low circulating androgen conditions [ 15 , 16 ].”
Testosterone Replacement Therapy on the Natural History of Prostate Disease
Moore, A., Butcher, M. J., & Köhler, T. (2015) · Current Urology Reports · doi:10.1007/s11934-015-0526-6 · Cited by 12
Perspectives on designs of antiandrogens for prostate cancer
Estébanez‐Perpiñá, E., Jouravel, N., & Fletterick, R. J. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.10.1341 · Cited by 12
“(2007) 2(10) The selection for resistant cells may be helped by endogenous androgens even during medical castration, as 20 – 30% of intraprostatic androgens remain [62] .”
BackgroundDevos, G., Vansevenant, B., Meerleer, G. D., Clinckaert, A., Devlies, W., Claessens, F., Graefen, M., Steuber, T. P., Briganti, A., TAILLE, A. D. L., et al. (2021) · World Journal of Urology · doi:10.1007/s00345-021-03611-x · Cited by 12
The basic biochemistry and molecular events of hormone therapy
Mostaghel, E. A., Montgomery, B., & Lin, D. W. (2007) · Current Urology Reports · doi:10.1007/s11934-007-0010-z · Cited by 14
“However, persistent androgen levels and androgen receptor–regulated gene expression have recently been demonstrated in benign tissues from castrate subjects without prostate cancer [ 43 ], as well as in tumor samples from castrate patients with localized disease receiving short-term (3 to 6 months’) neoadjuvant ADT [4…”
BackgroundSelf-citationAndrogen annihilation as a new therapeutic paradigm in advanced prostate cancer
Rove, K. O., & Crawford, E. D. (2013) · Current Opinion in Urology · doi:10.1097/mou.0b013e32835fa889 · Cited by 17
“Despite rendering men castrate (serum testosterone <50 ng/dl), persistent levels of testosterone (20%) and DHT (30%) remain within the prostate after GnRH agonist therapy, derived from the intraprostatic conversion of adrenal steroids and steroids from the cancer itself [14].”
BackgroundArai, S., Shibata, Y., Nakamura, Y., Kashiwagi, B., Uei, T., Tomaru, Y., Miyashiro, Y., Honma, S., Hashimoto, K., Sekine, Y., et al. (2012) · Andrology · doi:10.1111/j.2047-2927.2012.00026.x · Cited by 12
“In healthy men, chemical castration for 1 month causes a 70–80% decline in the intraprostatic T level (Page et al., 2006).”
BackgroundJonnalagadda, B., Arockiasamy, S., & Krishnamoorthy, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118208 · Cited by 11
Kühn, C. M., Strasser, H., Romming, A., Wullich, B., & Goebell, P. J. (2015) · Urologia Internationalis · doi:10.1159/000371725 · Cited by 11
Is Dihydrotestosterone a Classic Hormone?
Anawalt, B. D. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00091 · Cited by 14
Circulating sex steroids coregulate adipose tissue immune cell populations in healthy men
Rubinow, K. B., Chao, J. H., Hagman, D. K., Kratz, M., Yserloo, B. V., Gaikwad, N. W., Amory, J. K., & Page, S. T. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00075.2017 · Cited by 11
“Dissociations between serum and tissue-specific sex steroid levels also have been observed in other tissues, as clearly demonstrated by lack of associations between circulating and intraprostatic androgen levels (66, 77).”
BackgroundSelf-citationKim, W., Jones, J. O., Diamond, M., Haqq, C., Molina, A., Small, E. J., & Ryan, C. J. (2014) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.27 · Cited by 11
Canonical and Noncanonical Androgen Metabolism and Activity
Storbeck, K., & Mostaghel, E. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_11 · Cited by 12
Self-citationPaying the price for standing tall: Fluid mechanics of prostate pathology
Gat, Y., Joshua, S., Vuk‐Pavlović, S., & Goren, M. (2020) · The Prostate · doi:10.1002/pros.24051 · Cited by 10
Takizawa, I., Hara, N., Nishiyama, T., Isahaya, E., Hoshii, T., & Takahashi, K. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.06.115 · Cited by 9
Oestrogens and Prostate Cancer: Novel Concepts about an Old Issue
Briganti, A. (2008) · European Urology · doi:10.1016/j.eururo.2008.12.004 · Cited by 8
“Previous studies showed a weak correlation between serum and intraprostatic androgen levels [5,6].”
BackgroundHu, M., Xin, D., Chen, J., Sun, G., Wang, Y., & Na, Y.-Q. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08442.x · Cited by 7
Current and potential targets for drug design in the androgen receptor pathway for prostate cancer
Guddati, A. K. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1455662 · Cited by 7
“A positive correlation has been observed between the concentration of DHEA and DHT in these tissues [71,75].”
BackgroundCombining Prostate Cancer Radiotherapy with Therapies Targeting the Androgen Receptor Axis
Ghashghaei, M., Kucharczyk, M. J., Elakshar, S. H., Muanza, T. M., & Niazi, T. M. (2019) · Current Oncology · doi:10.3747/co.26.5005 · Cited by 7
Baker, A., Syed, A., Mohany, M., Elgorban, A. M., Khan, M. S., & Al-Rejaie, S. S. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.10.005 · Cited by 8
Preoperative therapy for localized prostate cancer: A comprehensive overview
Hu, J., Hsu, J., Bergerot, P. G., Yuh, B. E., Stein, C. A., & Pal, S. K. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.10.012 · Cited by 7
Current and Emerging Therapies
(2009) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814271325_0006 · Cited by 7
Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review
Kim, H., & Kim, J. K. (2022) · The World Journal of Men s Health · doi:10.5534/wjmh.210139 · Cited by 7
Han, H., Zhou, X., Qian, X.-S., Feng, S., Tian, L., & Zhang, X.-D. (2016) · Andrologia · doi:10.1111/and.12546 · Cited by 6
“Some studies have used radioimmunoassay to determine testosterone levels (Jarow et al., 2001; Page et al., 2006).”
BackgroundResultRelationship Between Second to Fourth Digit Ratios and Benign Prostatic Hyperplasia in Aging Men
Manjunatha, R. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/11992.5937 · Cited by 6
Metabolism of adrenal androgen and its impacts on prostate cancer after castration
Hu, M., & Na, Y.-Q. (2008) · Chinese Medical Journal · doi:10.1097/00029330-200802020-00016 · Cited by 7
Is Men's Health Just a Single Letter?
Anawalt, B. D. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4362 · Cited by 7
“For example, changes in serum hormone levels do not correlate well with prostate hormone levels when serum hormone levels are altered by treatment or experimentally induced castration (9, 10).”
BackgroundChang, J., Choi, S., Kim, K., & Park, S. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050733 · Cited by 5
“A previous population-based cohort study showed that androgen deprivation therapy (ADT), which reduces serum T, DHT, and other androgens [18,19], increased the risk of MI and stroke among prostate cancer patients [8], possibly due to harmful metabolic effects [6,7].”
Ayele, H. T., Reynier, P., Azoulay, L., Platt, R. W., Benayoun, S., & Filion, K. B. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.06.021 · Cited by 5
Deiktakis, E. E., Ieronymaki, E., Zarén, P., Hagsund, A., Wirestrand, E., Malm, J., Tsatsanis, C., Huhtaniemi, I. T., Giwercman, A., & Giwercman, Y. L. (2022) · Endocrine Connections · doi:10.1530/ec-21-0639 · Cited by 5
Alyamani, M., Michael, P., Hettel, D. R., Thomas, L. J., Lundy, S. D., Berk, M., Patel, M., Li, J., Rashidi, H., McKenney, J. K., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171117 · Cited by 4
“However, the androgen changes in the prostate that follow do not always clearly reflect changes in circulating T (16–18).”
Tissue Levels of Androgens in Castration-Recurrent Prostate Cancer
Mohler, J. L., & Titus, M. A. (2009) · Springer eBooks · doi:10.1007/978-0-387-69179-4_23 · Cited by 4
“Mizokami et al. (2004) showed average tissue DHT levels measured using LC/MS/MS decreased 75% in prostatectomy specimens obtained after 3‐6 months of ADT, and Nishiyama et al. (2004) found tissue DHT concentration decreased 75% in prostate tissue from 30 men receiving ADT for 6 months.”
MethodRipert, T., Crouzet, S., Ploussard, G., TAILLE, A. D. L., & Robert, G. (2013) · The French Journal of Urology · doi:10.1016/s1166-7087(13)70042-3 · Cited by 4
Poirier, D., Maltais, R., Rousseau, J. A., Roy, J., Phoenix, S., Cortés‐Benítez, F., & Lecomte, R. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106145 · Cited by 4
RhoGDIα downregulates androgen receptor signaling in prostate cancer cells
Zhu, Y., Liu, C., Tummala, R., Nadiminty, N., Lou, W., & Gao, A. C. (2013) · The Prostate · doi:10.1002/pros.22615 · Cited by 4
“…mutations or amplification of AR to induce hypersensitivity to low levels of intracrine androgens [19–23]; increased androgen biosynthesis [24–30]; the activation of alternate signal transduction pathways involving growth factor-and cytokine-mediated AR activation and downstream receptor…”
RetractedCell Biology of Prostate Cancer and Molecular Targets
Gleave, M. E., Cox, M., & Wang, Y. Z. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_1 · Cited by 4
Androgen Receptor in Health and Disease
Marcelli, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-46086-4_2 · Cited by 3
A resource-based mechanistic framework for castration-resistant prostate cancer (CRPC)
Vibishan, B., Harshavardhan, B. V., & Dey, S. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111806 · Cited by 4
Systemic Therapy of Bone Metastases
Kamposioras, K. V., & Briasoulis, E. C. (2013) · Cancer metastasis · doi:10.1007/978-94-007-7569-5_13 · Cited by 3
Balk, S. P. (2009) · Springer eBooks · doi:10.1007/978-0-387-69179-4_5 · Cited by 4
Standard androgen deprivation therapy for prostate cancer
Sharifi, N. (2010) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.02.002 · Cited by 4
Rationale for statins in the chemoprevention of prostate cancer
Hamilton, R. J., & Freedland, S. J. (2008) · Current Prostate Reports · doi:10.1007/s11918-008-0016-0 · Cited by 3
Do We Really Need New Trials on Fulvestrant in Prostate Cancer?
Féchon, A., & Droz, J. (2010) · Onkologie · doi:10.1159/000271605 · Cited by 3
Choi, Y. H., Kim, H. Y., Yang, S.-H., Koh, J. S., Choi, J. B., & Lee, D. S. (2025) · The World Journal of Men s Health · doi:10.5534/wjmh.250105 · Cited by 2
“For instance, Page et al [26] revealed that intraprostatic dihydrotestosterone levels were 10-fold higher than circulating dihydrotestosterone level.”
Androgen Suppression: The Good, The Bad and The Ugly
Corey, E. (2012) · Andrology-Open Access · doi:10.4172/2167-0250.1000e106 · Cited by 2
“A recent report shows that treatment with a GnRH antagonist decreased serum testosterone by 94%, while intra-prostatic testosterone and dihydrotestosterone fell only 70% and 80%, respectively [7].”
BackgroundAndrogen receptor-dependent mechanisms mediating therapy resistance in prostate cancer
Saker, Z., Rizk, M., & Nabha, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16032-5.00004-x · Cited by 3
Prostate Cancer: Current and Emerging Therapies
Abhijit, M., & Njar, V. C. O. (2011) · InTech eBooks · doi:10.5772/23893 · Cited by 2
“Also, it has been shown that despite castration levels of plasma testosterone, DHT levels in the prostate itself remain at 15–40% of that at baseline [59].”
Testosterone deficiency syndrome and prostate cancer: illustrative annotations for a debate
Morales, Á., & Black, A. M. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.528 · Cited by 2
“They also show that about 30% of intraprostatic testosterone and dehydrotestosterone are maintained following castration.(9) Is it appropriate to wait for a potential recovery of testicular function in men who were treated with androgen deprivation and radiotherapy? The evidence is that for those in whom a recovery oc…”
BackgroundThe Mechanism of Androgen Deprivation and the Androgen Receptor
Bayraktar, S. (2010) · The Open Prostate Cancer Journal · doi:10.2174/1876822901003010047 · Cited by 2
“remained at 20-30% of control values [81].”
Murez, T., Basset, V., Audenet, F., Lebrét, T., & Branchereau, J. (2013) · The French Journal of Urology · doi:10.1016/s1166-7087(13)70040-x · Cited by 2
Second-Line Hormonal for Castrate-Resistant Prostate Cancer
Parihar, J. S., & Kim, I. Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00057-8 · Cited by 4
Toprak, T., Arslan, U., Kutluhan, M. A., Şahin, A., Akgül, K. T., Şahan, A., & Verit, A. (2020) · Andrologia · doi:10.1111/and.13529 · Cited by 2
“Testosterone, especially DHT, is an important factor in the development of the prostate gland (Feldman & Feldman, 2001; Page et al., 2006).”
BackgroundAndrogens and Benign Prostatic Hyperplasia
Farrant, M. T., & Page, S. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99445-5 · Cited by 2
Self-citationMorales, Á. (2017) · Canadian Urological Association Journal · doi:10.5489/cuaj.4652 · Cited by 1
Androgen Receptor in Health and Disease
Hohl, A., & Marcelli, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_2 · Cited by 2
Milecki, T., Antczak, A., Kwias, Z., & Milecki, P. (2014) · Współczesna Onkologia · doi:10.5114/wo.2014.42723 · Cited by 4
“However, numerous studies in which concentrations of testosterone and its derivatives were measured in the hormone-refractory cancer tissue provided evidence that castration therapy does not entirely eliminate androgens from the tumour cell environment, despite castration levels of testosterone in peripheral blood [4].”
BackgroundNew Pharmacotherapies in the Treatment of Advanced Prostate Cancer
El-Ayass, W., El-Amm, J., Jain, M. M., & Aragon‐Ching, J. B. (2010) · Clinical Medicine Insights Urology · doi:10.4137/cmu.s5075 · Cited by 1
McNerney, E. M., & Oñate, S. A. (2015) · Nuclear Receptor Research · doi:10.11131/2015/101186 · Cited by 1
Achukwu, P. U., Omorodion, N. T., & Igwilo, C. K. (2017) · Health Care Current Reviews · doi:10.4172/2375-4273.1000213 · Cited by 1
HORMONAL DISTURBANCES IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA
Sahi, I. S., Ramadhan, M. A., & Khadim, S. U. (2013) · Basrah Journal of Surgery · doi:10.33762/bsurg.2013.73620 · Cited by 1
The basic biochemistry and molecular events of hormone therapy
Mostaghel, E. A., Montgomery, B., & Lin, D. W. (2008) · Current Prostate Reports · doi:10.1007/s11918-008-0009-z · Cited by 1
Self-citationHara, T. (2010) · Folia Pharmacologica Japonica · doi:10.1254/fpj.136.192 · Cited by 1
Approaches Targeting Androgen Synthesis (CYP 17 Inhibitors)
Siegel, A. P., & Ryan, C. J. (2014) · Current clinical urology · doi:10.1007/978-1-4939-1176-9_7 · Cited by 1
Analyse d’articles — avec la collaboration de la Société Francophone de Médecine Sexuelle (SFMS)
Buvat, J. (2012) · Basic and Clinical Andrology · doi:10.1007/s12610-012-0174-3
Unraveling of the major genetic defects in prostate cancer
Hermans, K. G. (2009) · EUR Research Repository (Erasmus University Rotterdam)
Mechanisms of Chinese Red Yeast Rice Inhibition of Prostate Cancer Growth
Hong, M. Y. (2009) · Defense Technical Information Center (DTIC) · doi:10.21236/ada502738
Molecular mechanisms of androgen receptor functions
Steketee, K. (2007) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 1
Znaczenie terapii hormonalnej u pacjentów z przerzutowym opornym na kastrację rakiem stercza
Milecki, T., & Antczak, A. (2014) · Zeszyty Naukowe WCO Letters in Oncology Science · doi:10.1016/j.onko.2014.03.001
Vis, A. N. (2012) · Tijdschrift voor Urologie · doi:10.1007/s13629-012-0007-3
Hall, S. A., Page, S. T., Travison, T. G., Montgomery, B., Link, C. L., & McKinlay, J. B. (2007) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.07.024
Self-citationMechanisms behind growth of castration-resistant prostate cancer bone metastases
Jernberg, E. (2013) · DiVA at Umeå University (Umeå University)
Tavakoli, I. (2013) · cIRcle (University of British Columbia) · doi:10.14288/1.0072850 · Cited by 2
“New studies also confirm that tumor cells are capable of synthesizing estrogen and androgen from other precursors [31].”
Background
Metadata
- Authors
- Page, S. T., Lin, D. W., Mostaghel, E. A., Hess, D. L., True, L. D., Amory, J. K., Nelson, P. S., Matsumoto, A. M., & Bremner, W. J.
- Affiliations
- VA Puget Sound Health Care System (US)
- Departments of Medicine (S.T.P., E.A.M., J.K.A., P.S.N., A.M.M., W.J.B.), Seattle, Washington 98195
- Oregon National Primate Research Center (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Page, Stephanie T.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-10-01
- Volume
- 91
- Issue
- 10
- Pages
- 3850-3856
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2155279970
- Cited by
- 229
- References
- 43
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 9 · 2022: 6 · 2021: 7 · 2020: 6 · 2019: 8 · 2018: 5 · 2017: 10 · 2016: 8 · 2015: 11 · 2014: 19 · 2013: 21 · 2012: 19
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5u54hd012629-31)
- National Institute on Aging (K23AG027238)
- National Cancer Institute (CA 97186, P50CA097186)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065204, DK65204, DK 65083, K23DK065083)
- National Center for Research Resources (RR-00163.)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD042454, U54-HD-12629)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- medical castration, GnRH antagonist, acyline, testosterone gel, dihydrotestosterone, prostate-specific antigen, androgen receptor, apoptosis, healthy men
- MeSH terms
- Adult, Androgens, Follicle Stimulating Hormone, Humans, Immunohistochemistry, Luteinizing Hormone, Male, Middle Aged, Orchiectomy, Prostate, Dihydrotestosterone, Testosterone, Prostate-Specific Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.